Logo do repositório

Percorrer por autor "Pinto, Fausto J."

A mostrar 1 - 2 de 2
  • Lipid-lowering therapy and LDL cholesterol control among high- and very high-risk patients in Portugal: An analysis of the SANTORINI study
    Publication . Aguiar, Carlos; Aguiar, Patrício; Duarte, João Sequeira; Gil, Victor; Mimoso, Jorge; Monteiro, Pedro; Pinto, Fausto J.; Pinto, Fernando; Raposo, João; von Hafe, Pedro; Ruivo, Jorge A.; Teixeira, Carla; Catapano, Alberico L.; Ray, Kausik K.
    Introduction and objectives: The SANTORINI study is the first large-scale, European observational study conducted following the release of the 2019 European Society of Cardiology/European Atherosclerosis Society ESC/EAS guidelines on dyslipidemia management. This analysis aims to assess lipid-lowering therapy (LLT) use and low-density lipoprotein cholesterol (LDL-C) goal attainment in patients at high or very high cardiovascular (CV) risk enrolled in Portugal. Methods: In Portugal, 117 patients were enrolled across 10 sites between September 2020 and February 2021. Paired LDL-C values at baseline and one-year follow-up were available for 102 patients. LDL-C levels, LLT utilization patterns, and LDL-C goal attainment (as per the 2019 ESC/EAS guidelines) were assessed at both time points and compared with the broader European cohort, excluding Portuguese participants. Results: Over the one-year follow-up, the use of statin monotherapy decreased from 49.5% to 45.2%, while combination therapy with statin and ezetimibe increased from 35.9% to 40.9%. LLT intensity was escalated in 12.8% of patients, unchanged in 79.5%, and de-escalated in 6.0%. Mean LDL-C levels were similar between baseline and one-year follow-up: corresponding values were 90.2 mg/dL and 90.1 mg/dL in high-risk patients, and 74.1 mg/dL and 75.2 mg/dL in very high-risk patients. LDL-C goal attainment declined from 34.1% to 22.7% in high-risk patients and 27.6% to 22.4% in very high-risk patients. Conclusions: The Portuguese cohort of the SANTORINI study demonstrates both encouraging developments and ongoing challenges in the real-world management of dyslipidemia following the 2019 ESC/EAS guidelines. Reasons for lack of LLT intensification and factors underlying worsening rates for LDL-C goal attainment should be explored. (c) 2025 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    2026-02Artigo científico Acesso aberto Ver mais
  • Old habits die hard: Can AI help bring coronary angiography Into the 21st Century?
    Publication . Menezes, Miguel Nobre; Oliveira, Catarina Simões; Silva, João Lourenço; Silva, Beatriz Valente; Marques, João Silva; Guerreiro, Cláudio; Guedes, João Pedro; Oliveira-Santos, Manuel; Oliveira, Arlindo L.; Pinto, Fausto J.
    Coronary angiography (CAG) was pioneered in the 1950s by Eduardo Coelho (who performed the first nonselective in vivo CAG in 1952 at the Santa Marta Hospital in Lisbon, Portugal) and Frank Mason Sones Jr (who performed the first selective CAG in vivo in 1958 at the Cleveland Clinic in Ohio, USA). Sones further developed the technique by contributing to the development of the C-arm, enabling multiangular views and a comprehensive assessment of coronary artery anatomy and disease. This approach remains essentially the same today. When interpreting CAG images, an essential step is the assessment of the severity/significance of coronary lesions, paramount for considering revascularization. Furthermore, the presence of significant lesions increases the risk of cardiovascular events and symptoms, rendering optimal medical therapy mandatory for addressing both.
    2024-08Artigo científico Acesso aberto Ver mais